Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt repayments

Daily Values

Growth Metrics

Standard Biotools (LAB) Asset Writedowns and Impairment (2019 - 2022)

Standard Biotools (LAB) has disclosed Asset Writedowns and Impairment for 2 consecutive years, with -$26000.0 as the latest value for Q4 2022.

Quarterly Asset Writedowns and Impairment changed N/A to -$26000.0 in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $3.5 million through Dec 2023, changed 0.0% year-over-year, with the annual reading at $3.5 million for FY2022, N/A changed from the prior year.
Asset Writedowns and Impairment for Q4 2022 was -$26000.0 at Standard Biotools, down from $3.5 million in the prior quarter.
The five-year high for Asset Writedowns and Impairment was $3.5 million in Q2 2022, with the low at -$26000.0 in Q4 2022.